Core Viewpoint - The article highlights the investment opportunities in the A-share market for October, emphasizing a structural trend where growth sectors, particularly technology and high-end manufacturing, are expected to lead the market due to supportive policies, industry catalysts, and a loose liquidity environment [1][6]. Group 1: Recommended Stocks - A total of 111 stocks have been recognized by 13 brokerage firms in their October "golden stock" lists, with notable mentions including SMIC, WuXi AppTec, Huayou Cobalt, Hikvision, and Haier Smart Home [1][3]. - The stocks with the highest recommendation frequency include SMIC, WuXi AppTec, Huayou Cobalt, Hikvision, and Haier Smart Home, each receiving recommendations from two brokerage firms [3][4]. Group 2: Industry Insights - The technology sector, particularly TMT (Technology, Media, and Telecommunications), is expected to be a key focus area, driven by liquidity and market trends, with significant catalysts such as ongoing industry advancements and the anticipated interest rate cuts by the Federal Reserve [4][8]. - SMIC is positioned as a leading player in the advanced wafer foundry market, benefiting from the surge in AI chip demand and domestic substitution trends, with revenue from advanced processes projected to grow by 68% year-on-year by 2025 [5]. - WuXi AppTec is expected to see growth in orders due to an uptick in global biotech investment and demand for innovative drug CDMO services, driven by recent positive performance from major CXO companies [5]. Group 3: Market Outlook - Historical data suggests that the A-share market typically experiences a rebound after the National Day holiday, with over 70% probability of an increase in the first week post-holiday, supported by various upcoming significant events [7]. - The market is anticipated to gain momentum from the convergence of favorable policies, confirmed earnings bottoms, and adequate liquidity, leading to a potential new upward trend [7][8]. - The focus for October is expected to be on technology growth sectors, with the Hong Kong market also benefiting from unique structural factors and external liquidity expectations [8].

Core Viewpoint - WuXi AppTec (603259)(02359) announced the conversion and issuance of 14.1858 million H-shares based on a $500 million zero-coupon secured convertible bond maturing in 2025, effective September 30, 2025 [1] Group 1 - The company will issue H-shares as part of the conversion of the convertible bond [1] - The convertible bond is valued at $500 million and is set to mature in 2025 [1] - The total number of H-shares to be issued is 14.1858 million [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年9月30日 (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | ...

Market Overview - The Shanghai Composite Index rose by 0.52% on September 30, with 19 out of 28 sectors experiencing gains, led by the non-ferrous metals and defense industries, which increased by 3.22% and 2.59% respectively [1] - The pharmaceutical and biological industry saw an increase of 1.40% [1] - The sectors with the largest declines were telecommunications and non-bank financials, which fell by 1.83% and 1.14% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.303 billion yuan, with only four sectors seeing net inflows [1] - The defense industry had the highest net inflow of 2.059 billion yuan, while the non-ferrous metals sector followed with a net inflow of 1.984 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 11.405 billion yuan, followed by telecommunications with a net outflow of 5.936 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector had a net inflow of 984 million yuan, with 310 out of 475 stocks rising, including two hitting the daily limit [2] - The top three stocks by net inflow were WuXi AppTec with 1.113 billion yuan, followed by Hengrui Medicine and Yong'an Pharmaceutical with 431 million yuan and 134 million yuan respectively [2] - Nine stocks in this sector saw net outflows exceeding 50 million yuan, with C Jianfa Zhi leading at 896.727 million yuan [3] Top Gainers in Pharmaceutical Sector - WuXi AppTec increased by 6.42% with a turnover rate of 2.86% and a main capital flow of 1.112 billion yuan [2] - Hengrui Medicine rose by 3.40% with a turnover rate of 0.91% and a main capital flow of 431 million yuan [2] - Yong'an Pharmaceutical saw a rise of 6.92% with a turnover rate of 16.56% and a main capital flow of 134 million yuan [2] Top Losers in Pharmaceutical Sector - C Jianfa Zhi decreased by 15.04% with a turnover rate of 52.49% and a main capital flow of -896.727 million yuan [3] - Xiangrikui rose by 2.00% but had a net outflow of 854.806 million yuan [3] - Jilin Aodong fell by 1.91% with a net outflow of 797.945 million yuan [3]

Core Insights - The medical services sector experienced a rise of 2.89% on September 30, with WuXi AppTec leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Medical Services Sector Performance - WuXi AppTec (603259) closed at 112.03, with a gain of 6.42% and a trading volume of 707,400 shares, amounting to a transaction value of 7.792 billion [1] - Other notable performers included Haoyuan Pharmaceutical (688131) with a 6.36% increase, Boteng Co., Ltd. (300363) up by 5.31%, and MediSino (688202) rising by 4.85% [1] - The sector saw a net inflow of 1.095 billion in main funds, while retail investors experienced a net outflow of 549 million [2][3] Fund Flow Analysis - WuXi AppTec had a net inflow of 926 million from main funds, but a net outflow of 659 million from speculative funds [3] - Other companies like Kanglong Chemical (300759) and Kailai Ying (002821) also showed significant fund flow dynamics, with varying levels of net inflow and outflow [3] - The overall trend indicates a mixed sentiment among retail and institutional investors within the medical services sector [2][3]

Group 1 - The Hang Seng Index rose by 0.87%, while the Hang Seng Tech Index increased by 2.24% [1] - Semiconductor stocks experienced significant gains, with Hua Hong Semiconductor rising nearly 11% and SMIC increasing by almost 4% [1] - Spot gold prices reached new highs, leading to a strong performance in gold stocks, with Zijin Mining International surging over 68% and MKS PAMP Group rising more than 4% [1] Group 2 - Ganfeng Lithium and WuXi AppTec both saw increases of over 8%, while Tianqi Lithium rose by more than 5% [1]

Core Viewpoint - The Hong Kong medical sector is experiencing significant gains, with companies like WuXi AppTec rising over 8%, indicating a strong market interest in AI healthcare and CXO services [1] Group 1: Market Performance - The Hong Kong medical sector saw a collective rise, with notable increases in stocks such as WuXi AppTec, Yaoshi Bang, Crystal Tech Holdings, Zai Lab, and MicroPort, reflecting a bullish sentiment in the market [1] - The Hong Kong Stock Connect medical ETF focusing on AI healthcare and CXO (520510) increased by nearly 3%, while the Hang Seng Medical ETF (159892) focusing on innovative drugs rose over 2% [1] Group 2: Industry Trends - Changjiang Securities reports that an increasing number of Chinese pharmaceutical companies are establishing original innovation capabilities and developing mature R&D technology platforms [1] - Chinese innovative pharmaceutical companies are targeting unmet clinical needs and continuously exploring new targets and mechanisms, leading to the emergence of a batch of innovative drugs with international competitiveness, including FIC (First-in-Class) and BIC (Best-in-Class) potential [1]

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Core Viewpoint - The recent announcement by Trump regarding a 100% tariff on all brand/patent drugs starting in October has led to a strong performance in the pharmaceutical sector, particularly among Chinese innovative drug companies, which are not expected to be significantly impacted by this policy [1][1]. Group 1: Stock Performance - Chinese pharmaceutical stocks have shown strong gains, with Heptares Therapeutics (02142) up 8.2% to HKD 15.71, Zai Lab (09688) up 6.83% to HKD 26.6, Innovent Biologics (09969) up 6.61% to HKD 18.87, and WuXi AppTec (603259) (02359) up 5.37% to HKD 115.7 [1][1]. Group 2: Tariff Impact Analysis - Trump's tariff policy applies only to brand/patent drugs and excludes generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) [1][1]. - According to CMB International, the impact on China's innovative drug industry chain is limited, and there is no need for excessive concern [1][1]. - Most Chinese companies have either established production capacity in the U.S. or outsourced production to local Contract Manufacturing Organizations (CMOs), which mitigates the immediate impact of the tariffs [1][1]. Group 3: Export Dynamics - The majority of Chinese innovative drugs exported are in the form of APIs or raw herbal extracts, which are not affected by the new tariff policy, while the proportion of finished drug exports remains low [1][1]. - The investment timeline for multinational corporations (MNCs) to build factories in the U.S. will take time, leading to limited direct impact on CXO orders in the short term [1][1]. Group 4: Future Catalysts - Upcoming catalysts include the ESMO conference scheduled for mid to late October and the results of the medical insurance negotiations along with the first version of the commercial insurance innovative drug catalog expected to be announced in October to November [1][1].